{name}
{subtitle}
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~10 mi. (Solna, Sweden, +176 more cities)
facility
Karolinska Universitetssjukhuset Solna ( Site 2220)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~10 mi. (Solna, Sweden, +115 more cities)
facility
Karolinska Universitetssjukhuset Solna ( Site 2000)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~11 mi. (Stockholm, Sweden, +144 more cities)
facility
Karolinska Universitetssjukhuset Solna ( Site 2100)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~11 mi. (Stockholm, Sweden, +89 more cities)
facility
Karolinska Universitetssjukhuset Solna-Tema Cancer - ME Bröst- endokrina tumörer och sarkom ( Site 1
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~11 mi. (Stockholm, Sweden, +147 more cities)
facility
Karolinska Universitetssjukhuset ( Site 0784)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~11 mi. (Stockholm, Sweden, +199 more cities)
facility
Karolinska Universitetssjukhuset, Huddinge ( Site 0689)
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~11 mi. (Stockholm, Sweden, +163 more cities)
facility
Karolinska Universitetssjukhuset Solna ( Site 1212)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
city
~11 mi. (Stockholm, Sweden, +29 more cities)
facility
Karolinska Universitetssjukhuset Solna ( Site 1202)
condition
Pancreatic Neuroendocrine Tumor, +1 more condition